Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)

PHASE2CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Age Related Macular Degeneration
Interventions
DRUG

ranibizumab (Lucentis(R))

0.5 mg intravitreal injection once a month for 4 months, then as needed for 2 months

Trial Locations (1)

95817

University of California, Davis, Sacramento

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Lawrence S. Morse, MD

OTHER

NCT00931489 - Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD) | Biotech Hunter | Biotech Hunter